ArticleEJIFCC2026
Biochemical Clues in unravelling the Puzzle of Anti- synthetase Syndrome.
Article in EJIFCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-synthetase syndrome (ASSD or ASyS) is a rare, systemic autoimmune disorder characterized by the presence of anti-aminoacyl transfer RNA synthetase (anti-ARS) antibodies, most commonly anti-Jo-1. It presents with a combination of myositis, interstitial lung disease (ILD), arthritis, Raynaud's phenomenon, mechanic's hands, and constitutional symptoms, often posing significant diagnostic challenges. We report the case of a 49-year-old male carpenter who presented with persistent cough, progressive dyspnoea, proximal muscle weakness, and joint pain. High-resolution computed tomography (HRCT) of the chest revealed interstitial lung disease with bilateral basal end-inspiratory crepitations noted on physical examination. Serological testing demonstrated anti-Jo-1 antibody positivity, confirming the diagnosis of anti-synthetase syndrome. The patient was initiated on glucocorticoids, hydroxychloroquine, and steroid-sparing immunosuppressive therapy, resulting in symptomatic and functional improvement. This case underscores the importance of early recognition of anti-synthetase syndrome, particularly in patients presenting with unexplained ILD and musculoskeletal symptoms. Delayed diagnosis is often attributed to limited clinical awareness and the restricted availability of routine testing for anti-ARS antibodies, particularly anti-Jo-1, which significantly affects patient outcomes. ILD is a predominant and serious manifestation of ASyS and remains a strong predictor of disease-related morbidity and mortality. Anti-synthetase syndrome should be considered in patients with interstitial lung disease, muscle weakness, and inflammatory arthritis, especially when anti-Jo-1 antibodies are detected. Early diagnosis and immunosuppressive therapy are critical to improving prognosis and preserving lung function.
Indexed as
Identifiers
42730038PMC13563542What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.